Century Therapeutics (IPSC) Liabilities and Shareholders Equity (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $326.6 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 3.47% year-over-year to $326.6 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 26.75% decrease from a year earlier, with the FY2025 full-year figure at $223.7 million, down 36.67% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $326.6 million, up from $223.7 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for IPSC reached as high as $550.3 million in Q1 2022 and fell as low as $223.7 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $389.1 million across 5 years, with a median of $388.6 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity climbed 11.24% in 2022 and tumbled 37.03% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $486.5 million in 2022, then decreased by 25.87% to $360.7 million in 2023, then slipped by 2.07% to $353.2 million in 2024, then slumped by 36.67% to $223.7 million in 2025, then soared by 45.98% to $326.6 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $326.6 million in Q1 2026, $223.7 million in Q4 2025, and $244.7 million in Q3 2025.